IN2014DN07799A - - Google Patents
Info
- Publication number
- IN2014DN07799A IN2014DN07799A IN7799DEN2014A IN2014DN07799A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A IN 7799DEN2014 A IN7799DEN2014 A IN 7799DEN2014A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A
- Authority
- IN
- India
- Prior art keywords
- antibody
- present disclosure
- rob04
- angiogenesis
- pharmaceutical composition
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 4
- 230000003527 anti-angiogenesis Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Abstract
The present disclosure relates to an antibody having an anti angiogenesis activity. More specifically the present disclosure relates to an antibody against ROB04 and a pharmaceutical composition containing the antibody. An object of the present disclosure is to provide an anti ROB04 antibody having an anti angiogenesis effect a pharmaceutical composition or the like comprising the antibody a method for suppressing angiogenesis using the antibody etc. Another object of the present disclosure is to provide a method for producing the antibody. Solution The antibody of the present disclosure activates the downstream signal of ROB04 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present disclosure also exhibits an anti angiogenesis effect in in vivo models. Thus the problem has been solved.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (en) | 2012-04-27 | 2012-04-27 | Anti-robo4 antibody |
| JP2013011042A JP2014141434A (en) | 2013-01-24 | 2013-01-24 | Anti-robo4-antibody |
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07799A true IN2014DN07799A (en) | 2015-05-15 |
Family
ID=48670623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7799DEN2014 IN2014DN07799A (en) | 2012-04-27 | 2013-04-26 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9683040B2 (en) |
| EP (1) | EP2841457B1 (en) |
| JP (2) | JP5897205B2 (en) |
| KR (2) | KR101950898B1 (en) |
| CN (1) | CN104768973B (en) |
| AU (1) | AU2013254313B2 (en) |
| BR (1) | BR112014026649A2 (en) |
| CA (1) | CA2868074A1 (en) |
| CO (1) | CO7111295A2 (en) |
| DK (1) | DK2841457T3 (en) |
| ES (1) | ES2733434T3 (en) |
| IN (1) | IN2014DN07799A (en) |
| MX (1) | MX356749B (en) |
| MY (1) | MY166821A (en) |
| NZ (1) | NZ629291A (en) |
| PH (1) | PH12014502382B1 (en) |
| PL (1) | PL2841457T3 (en) |
| RU (1) | RU2682451C2 (en) |
| SG (1) | SG11201405718QA (en) |
| TW (1) | TWI606065B (en) |
| WO (1) | WO2013160879A1 (en) |
| ZA (1) | ZA201406235B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013254313B2 (en) * | 2012-04-27 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-ROBO4-antibody |
| EP4349997A3 (en) | 2015-09-24 | 2024-07-10 | Daiichi Sankyo Company, Limited | Anti-garp antibody |
| US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
| KR20210070643A (en) | 2019-12-05 | 2021-06-15 | 김명배 | self-developed wearable bridge |
| WO2023156437A1 (en) | 2022-02-16 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| WO2025045139A1 (en) * | 2023-08-31 | 2025-03-06 | 舒泰神（北京）生物制药股份有限公司 | Antibody specifically recognizing robo2 and use thereof |
| CN117384290B (en) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | Human ROBO1 binding molecules and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
| ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| JPH09506508A (en) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| EP3031917A1 (en) | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EA013563B1 (en) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies |
| US7498034B2 (en) * | 2000-11-06 | 2009-03-03 | Cancer Research Technology Limited | Imaging, diagnosis and treatment of disease |
| JP4583638B2 (en) * | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | Acetyllysine-recognizing monoclonal antibody and method for producing the same |
| CA2490713A1 (en) | 2002-06-27 | 2004-01-08 | University Of Utah Research Foundation | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| US20060099143A1 (en) | 2002-11-20 | 2006-05-11 | Roy Bicknell | Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis |
| EP1583830B1 (en) | 2003-01-07 | 2006-09-06 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| WO2008073441A2 (en) | 2006-12-11 | 2008-06-19 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
| KR20090114443A (en) * | 2007-02-09 | 2009-11-03 | 제넨테크, 인크. | Anti-RWF4 antibodies and uses thereof |
| TWI480050B (en) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | Anti-mst1r antibodies and uses thereof |
| AU2013254313B2 (en) * | 2012-04-27 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-ROBO4-antibody |
-
2013
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/en active
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en active Application Filing
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/en not_active Expired - Fee Related
- 2013-04-26 US US14/397,210 patent/US9683040B2/en not_active Expired - Fee Related
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/en not_active IP Right Cessation
- 2013-04-26 PL PL13730645T patent/PL2841457T3/en unknown
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 TW TW102115219A patent/TWI606065B/en not_active IP Right Cessation
- 2013-04-26 ES ES13730645T patent/ES2733434T3/en active Active
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/en not_active Expired - Fee Related
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/en not_active Ceased
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 MX MX2014012351A patent/MX356749B/en active IP Right Grant
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/en not_active Expired - Fee Related
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/en not_active Application Discontinuation
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382B1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/en unknown
-
2015
- 2015-12-11 US US14/966,292 patent/US9562096B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07799A (en) | ||
| HUE049171T2 (en) | Antibodies to Claudin 18.2 can be used in the diagnosis of cancer | |
| EP3421496C0 (en) | ANTIBODIES FOR THE TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | |
| EP2761554A4 (en) | SOCIAL PAYMENTS OF PROXIMITY | |
| EP2786664A4 (en) | PROCESS FOR PREPARING PULP FOR ELECTRONIC CIGARETTE AND CLASSIC NARGUILY | |
| EP2863910A4 (en) | COMPOSITIONS AND METHODS FOR REGULATING THE HOMEMYSTASIS OF GLUCOSE AND THE ACTION OF INSULIN | |
| AU341611S (en) | Dual function wine system | |
| UA115652C2 (en) | COMPOUND CONTAINING MODIFIED OLIGONUCLEOTIDE COMPLEMENTARY MIR-21 | |
| EP2917235A4 (en) | Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone | |
| EP3030244A4 (en) | Polyconjugates for delivery of rnai triggers to tumor cells in vivo | |
| PL2935595T3 (en) | Method and device for the production of biogas from biomass containing lignocellulose | |
| EP2832694A4 (en) | CRYSTAL GERM OF ZEOLITE DDR, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING DERMAL ZEOLITE FILM | |
| MX2015010429A (en) | Cetuximab with modified glycosylation and uses thereof. | |
| WO2014209905A3 (en) | Methods and compositions for detecting and diagnosing diseases and conditions | |
| IN2014MN02114A (en) | ||
| EP2742400A4 (en) | SUSPENSION AND / OR PROCESS SLOW DOWN FOR CONNECTED WATCH | |
| MX2014004211A (en) | Coating compositions for inorganic casting molds and cores, comprising formic acid esters, and use thereof. | |
| EP2771688A4 (en) | ANTI-PSA FREE ANTIBODIES AS DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC PRODUCTS FOR PROSTATE CANCER | |
| EP3031914A4 (en) | MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME | |
| AU343147S (en) | Easel | |
| EP3009008A4 (en) | CEREAL CONTAINING HERICIUM ERINACEUM AND PROCESS FOR PRODUCING THE SAME | |
| EP2714923A4 (en) | METHODS AND COMPOSITIONS FOR THE DETECTION OF FUNCTIONAL DIFFICULT CLOSTRIDIUM TOXINS | |
| IL243727A0 (en) | System and method for deriving material change attributes from curated and analyzed data signals over time to predict future changes in conventional predictors | |
| PL2994455T3 (en) | Method and technical process for the continuous synthesis of different ionic liquids | |
| IN2014MN01871A (en) |